The FDA on December 18, 2020 approved TAGRISSO® for adjuvant therapy after tumor resection in patients with Non-Small Cell Lung Cancer (NSCLC) whose tumors have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. TAGRISSO® is a product of AstraZeneca Pharmaceuticals LP.
Other Pages – Bottom Ad
Advertisement
Subscribe
